The system is available for patients whose mitral valves are not working properly due to severe mitral annular calcification.

The FDA gave the OK for the North Chicago-based medical device maker's Tendyne transcatheter mitral valve replacement.

The FDA approved Abbott's Tendyne minimally invasive heart replacement for mitral valve disease that could disqualify ...

Abbott (NYSE: ABT) announced today that it received FDA approval for its Tendyne transcatheter mitral valve replacement (TMVR ...

Abbott announced the FDA approved its transcatheter mitral valve replacement system for patients with severe mitral annular ...

During the meeting, issues related to process mapping, preoperative and postoperative steps, and possible directions for ...

The approval is tightly defined: the system will be for patients ineligible for surgery and with anatomy unfavorable for TEER ...

Abbott’s FreeStyle Libre continuous glucose monitoring technology is associated with a significant reduction in the risk of hospitalization for heart complications in people with diabetes, according ...

YEREVAN, May 30. /ARKA/. Armenia plans to introduce a program for the treatment of heart failure called “Artificial Heart.” ...

The US Food and Drug Administration has approved Abbott's Tendyne Transcatheter Mitral Valve Replacement (TMVR) system. It is indicated for patients with mitral valve disease caused by ...